Related Experiment Video
Updated: Aug 28, 2025

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer
Published on: February 9, 2024
Fbxo22 promotes cervical cancer progression via targeting p57Kip2 for ubiquitination and degradation
Min Lin1, Jianan Zhang1, Hakim Bouamar2
1Center for Uterine Cancer Diagnosis & Therapy Research of Zhejiang Province, Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325027, China.
Abstract:
F-box only protein 22 (FBXO22) is a key subunit of the Skp1-Cullin 1-F-box protein (SCF) E3 ubiquitin ligase complex. Little is known regarding its biological function and underlying molecular mechanisms in regulating cervical cancer (CC) progression. In this study, we aim to explore the role and mechanism of FBXO22 in CC progression. The correlation between FBXO22 and clinicopathological characteristics of CC was analyzed by tissue microarray. MTT, colony formation, flow cytometry, Western blotting, qRT-PCR, protein half-life, co-immunoprecipitation, ubiquitination, and xenograft experiments were performed to assess the functions of FBXO22 and potential molecular mechanisms of FBXO22-mediated malignant progression in CC. The expression of FBXO22 protein in CC tissues was higher than that in adjacent non-tumor cervical tissues. Notably, high expression of FBXO22 was significantly associated with high histology grades, positive lymph node metastasis, and poor outcomes in CC patients. Functionally, ectopic expression of FBXO22 promoted cell viability in vitro and induced tumor growth in vivo, while knockdown of FBXO22 exhibited opposite effects. In addition, overexpression of FBXO22 promoted G1/S phase progression and inhibited apoptosis in CC cells. Mechanistically, FBXO22 physically interacted with the cyclin-dependent kinase inhibitor p57Kip2 and subsequently mediated its ubiquitination and proteasomal degradation leading to tumor progression. FBXO22 protein level was found negatively associated with p57Kip2 protein levels in patient CC samples. FBXO22 promotes CC progression partly through regulating the ubiquitination and proteasomal degradation of p57Kip2. Our study indicates that FBXO22 might be a novel prognostic biomarker and therapeutic target for CC.
Insights
F-box only protein 22 (FBXO22) promotes cervical cancer (CC) progression by degrading p57Kip2. This study identifies FBXO22 as a potential prognostic biomarker and therapeutic target for CC.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- F-box only protein 22 (FBXO22) is a component of the SCF E3 ubiquitin ligase complex.
- The role of FBXO22 in cervical cancer (CC) progression is largely unknown.
Purpose of the Study:
- To investigate the function and molecular mechanisms of FBXO22 in CC progression.
- To evaluate FBXO22 as a potential prognostic biomarker and therapeutic target in CC.
Main Methods:
- Tissue microarray analysis of FBXO22 expression in CC tissues.
- In vitro assays (MTT, colony formation, flow cytometry, Western blotting, qRT-PCR, protein half-life, co-immunoprecipitation, ubiquitination).
- In vivo xenograft experiments.
Main Results:
- FBXO22 expression is upregulated in CC tissues and associated with advanced grade, lymph node metastasis, and poor prognosis.
- FBXO22 overexpression enhances CC cell viability, tumor growth, G1/S phase progression, and inhibits apoptosis.
- FBXO22 interacts with and promotes the ubiquitination and proteasomal degradation of p57Kip2, leading to CC progression.
Conclusions:
- FBXO22 drives CC progression by targeting p57Kip2 for degradation.
- FBXO22 represents a promising prognostic biomarker and therapeutic target for cervical cancer.
Related Concept Videos
Abnormal Proliferation
Anaphase Promoting Complex
Negative Regulator Molecules
Inhibition of Cdk Activity
The Intrinsic Apoptotic Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

